Literature DB >> 28434781

Design of novel HIV-1 protease inhibitors incorporating isophthalamide-derived P2-P3 ligands: Synthesis, biological evaluation and X-ray structural studies of inhibitor-HIV-1 protease complex.

Arun K Ghosh1, Margherita Brindisi2, Prasanth R Nyalapatla2, Jun Takayama2, Jean-Rene Ella-Menye2, Sofiya Yashchuk2, Johnson Agniswamy3, Yuan-Fang Wang3, Manabu Aoki4, Masayuki Amano4, Irene T Weber5, Hiroaki Mitsuya6.   

Abstract

Based upon molecular insights from the X-ray structures of inhibitor-bound HIV-1 protease complexes, we have designed a series of isophthalamide-derived inhibitors incorporating substituted pyrrolidines, piperidines and thiazolidines as P2-P3 ligands for specific interactions in the S2-S3 extended site. Compound 4b has shown an enzyme Ki of 0.025nM and antiviral IC50 of 69nM. An X-ray crystal structure of inhibitor 4b-HIV-1 protease complex was determined at 1.33Å resolution. We have also determined X-ray structure of 3b-bound HIV-1 protease at 1.27Å resolution. These structures revealed important molecular insight into the inhibitor-HIV-1 protease interactions in the active site.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Drug-resistance; HIV-1 protease; Isophthalamide; Synthesis; X-ray structure

Mesh:

Substances:

Year:  2017        PMID: 28434781      PMCID: PMC5617771          DOI: 10.1016/j.bmc.2017.04.005

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  28 in total

Review 1.  Current status and prospects of HIV treatment.

Authors:  Tomas Cihlar; Marshall Fordyce
Journal:  Curr Opin Virol       Date:  2016-03-28       Impact factor: 7.090

2.  In vitro selection of highly darunavir-resistant and replication-competent HIV-1 variants by using a mixture of clinical HIV-1 isolates resistant to multiple conventional protease inhibitors.

Authors:  Yasuhiro Koh; Masayuki Amano; Tomomi Towata; Matthew Danish; Sofiya Leshchenko-Yashchuk; Debananda Das; Maki Nakayama; Yasushi Tojo; Arun K Ghosh; Hiroaki Mitsuya
Journal:  J Virol       Date:  2010-09-01       Impact factor: 5.103

3.  Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors.

Authors:  Arun K Ghosh; Lisa M Swanson; Hanna Cho; Sofiya Leshchenko; Khaja Azhar Hussain; Stephanie Kay; D Eric Walters; Yasuhiro Koh; Hiroaki Mitsuya
Journal:  J Med Chem       Date:  2005-05-19       Impact factor: 7.446

4.  A simple, continuous fluorometric assay for HIV protease.

Authors:  M V Toth; G R Marshall
Journal:  Int J Pept Protein Res       Date:  1990-12

5.  Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease.

Authors:  S W Kaldor; V J Kalish; J F Davies; B V Shetty; J E Fritz; K Appelt; J A Burgess; K M Campanale; N Y Chirgadze; D K Clawson; B A Dressman; S D Hatch; D A Khalil; M B Kosa; P P Lubbehusen; M A Muesing; A K Patick; S H Reich; K S Su; J H Tatlock
Journal:  J Med Chem       Date:  1997-11-21       Impact factor: 7.446

6.  Probing multidrug-resistance and protein-ligand interactions with oxatricyclic designed ligands in HIV-1 protease inhibitors.

Authors:  Arun K Ghosh; Chun-Xiao Xu; Kalapala Venkateswara Rao; Abigail Baldridge; Johnson Agniswamy; Yuan-Fang Wang; Irene T Weber; Manabu Aoki; Salcedo Gomez Pedro Miguel; Masayuki Amano; Hiroaki Mitsuya
Journal:  ChemMedChem       Date:  2010-11-08       Impact factor: 3.466

7.  Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials.

Authors:  Ravindra Gupta; Andrew Hill; Anthony W Sawyer; Deenan Pillay
Journal:  Clin Infect Dis       Date:  2008-09-01       Impact factor: 9.079

8.  Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro.

Authors:  Yasuhiro Koh; Hirotomo Nakata; Kenji Maeda; Hiromi Ogata; Geoffrey Bilcer; Thippeswamy Devasamudram; John F Kincaid; Peter Boross; Yuan-Fang Wang; Yunfeng Tie; Patra Volarath; Laquasha Gaddis; Robert W Harrison; Irene T Weber; Arun K Ghosh; Hiroaki Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

9.  Design and synthesis of potent macrocyclic HIV-1 protease inhibitors involving P1-P2 ligands.

Authors:  Arun K Ghosh; Gary E Schiltz; Linah N Rusere; Heather L Osswald; D Eric Walters; Masayuki Amano; Hiroaki Mitsuya
Journal:  Org Biomol Chem       Date:  2014-09-21       Impact factor: 3.876

10.  Demonstration of sustained drug-resistant human immunodeficiency virus type 1 lineages circulating among treatment-naïve individuals.

Authors:  Stéphane Hué; Robert J Gifford; David Dunn; Esther Fernhill; Deenan Pillay
Journal:  J Virol       Date:  2009-01-21       Impact factor: 5.103

View more
  2 in total

1.  Highly Selective and Potent Human β-Secretase 2 (BACE2) Inhibitors against Type 2 Diabetes: Design, Synthesis, X-ray Structure and Structure-Activity Relationship Studies.

Authors:  Arun K Ghosh; Margherita Brindisi; Yu-Chen Yen; Emma K Lendy; Satish Kovela; Emilio Leal Cárdenas; Bhavanam Sekhara Reddy; Kalapala Venketeswara Rao; Deborah Downs; Xiangping Huang; Jordan Tang; Andrew D Mesecar
Journal:  ChemMedChem       Date:  2019-02-05       Impact factor: 3.466

2.  Design, synthesis, and X-ray studies of potent HIV-1 protease inhibitors incorporating aminothiochromane and aminotetrahydronaphthalene carboxamide derivatives as the P2 ligands.

Authors:  Arun K Ghosh; Ravindra D Jadhav; Hannah Simpson; Satish Kovela; Heather Osswald; Johnson Agniswamy; Yuan-Fang Wang; Shin-Ichiro Hattori; Irene T Weber; Hiroaki Mitsuya
Journal:  Eur J Med Chem       Date:  2018-09-18       Impact factor: 6.514

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.